QV Bioelectronics, a medical startup based in Alderley Park, has raised £2m in pre-Series A funding. The company is developing a technology called a GRACE implant, which is an Electric Field Therapy (EFT) device that aims to target dividing cancer cells within the brain, without affecting healthy cells. The funding will be used to support expanded pre-clinical studies to assess the safety and efficacy of the GRACE implant. The round was led by the Science Angel Syndicate and Fink Family Office, with participation from Northern Gritstone, ElbowBeach Capital, and existing investors SOSV and Catapult Ventures.
QV Bioelectronics has secured £2m in pre-Series A funding for its cutting-edge technology aimed at delivering transformative outcomes for glioblastoma patients. The funding will be used to support expanded pre-clinical studies to assess the safety and efficacy of the GRACE implant. The pre-Series A funding has come from a mix of new and existing deep tech investors, including the Science Angel Syndicate, Fink Family Office, Northern Gritstone, ElbowBeach Capital, SOSV, and Catapult Ventures.
The GRACE implant, an Electric Field Therapy (EFT) device, is a unique approach to treating glioblastoma, which is one of the most lethal types of cancer. QV Bioelectronics’ technology aims to target dividing cancer cells within the brain without affecting healthy cells. The funding will support expanded pre-clinical studies to assess the safety and efficacy of the GRACE implant, which is currently in pre-clinical development. The company’s implantable bioelectronics technology combines cutting-edge materials and interdisciplinary science, and the company hopes that its use in cancer care will provide longer, better quality lives for patients.
QV Bioelectronics is led and co-founded by biomedical engineer Dr Christopher Bullock, CEO, and Dr Richard Fu, a specialty registrar in neurosurgery and brain cancer researcher in the NHS. The company is pioneering the use of implantable bioelectronics in cancer care and is working with some of the UK’s leading neurosurgeons to ensure GRACE meets the needs of clinicians and fits seamlessly into existing patient treatment pathways. The GRACE implant is set to be implanted in patients already undergoing surgery to maximize patient safety and cost-effectiveness. Lord Stanley Fink, one of the investors in the pre-Series A funding round, has a personal connection to the cause as he suffered from a brain tumor over a decade ago.
QV Bioelectronics has raised £2m in pre-Series A funding to support its development of the GRACE implant, an Electric Field Therapy (EFT) device aimed at treating glioblastoma. The company’s cutting-edge technology combines the use of advanced materials, precision oncology, and surgical innovation. QV Bioelectronics is pioneering the use of implantable bioelectronics in cancer care and hopes its technology will provide longer, better quality lives for patients. The funding round was led by the Science Angel Syndicate and Fink Family Office, with participation from several other deep tech investors. The company’s co-founders are driven by the challenge to make a meaningful difference to the lives of brain cancer patients around the world.
